http://jpet.aspetjournals.org/content/early/2016/08/22/jpet.116.235127.abstract
- HyeonJu Kim1,
- Ying Wei1,
- Ji Yong Lee1,
- Yue Wu1,
- Yi Zheng1,
- Michael A. Moskowitz2, and
- John W. Chen1,*
+ Author Affiliations
- ↵*Address correspondence to: jwchen@mgh.harvard.edu
Abstract
The relationship between inflammation and
neurogenesis in stroke is currently not well understood. Focal ischemia
enhances
cell proliferation and neurogenesis in the
neurogenic regions including the subventricular zone (SVZ), dentate
gyrus (DG)
as well as non-neurogenic striatum, cortex in the
ischemic hemisphere. Myeloperoxidase (MPO) is a potent oxidizing enzyme
secreted during inflammation by activated
leukocytes and its enzymatic activity is highly elevated after stroke.
In this study,
we investigated whether inhibition of MPO activity
by a specific irreversible inhibitor, 4-aminobenzoic acid hydrazide
(ABAH)
or MPO-/- mice can increase neurogenesis after
transient middle cerebral artery occlusion (tMCAO) in mice. ABAH
administration
increased the number of proliferating 5-bromo-2'
deoxyuridine (BrdU)-positive cells expressing markers for neural stems
cells,
astrocytes, neuroprogenitors (Nestin), and
neuroblasts (doublecortin) in the ischemic SVZ, anterior SVZ (aSVZ),
striatum and
cortex. MPO inhibition also increased levels of
brain-derived neurotrophic factor (BDNF), phospho-cAMP response
element-binding
protein (pCREB Ser133), acetylated H3 (AcH3), and
NeuN to promote neurogenesis in the ischemic SVZ. ABAH treatment also
increased
chemokine CXC receptor 4 (CXCR 4) expression in the
ischemic SVZ. MPO-deficient mice treated with vehicle or ABAH both
showed
similar effects on the number of BrdU+ cells in the
ischemic hemisphere, demonstrating that ABAH is specific to MPO. Taken
together, our results underscore a detrimental role
of MPO activity to post-ischemia neurogenesis and that a strategy to
inhibit
MPO activity can increase cell proliferation and
improve neurogenesis after ischemic stroke.
No comments:
Post a Comment